Akero Therapeutics Inc

NASDAQ:AKRO  
27.26
+0.89 (+3.38%)
Earnings Announcements

Akero Therapeutics Reports Q4 And Full Year 2020 Financial Results

Published: 03/16/2021 13:08 GMT
Akero Therapeutics Inc (AKRO) - Akero Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.90

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.96

More details on our Analysts Page.